DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysisLinda M. Henricks, Jan H.M. Schellens, Geert Frederix et al.|The Lancet Oncology|2018Cited by 419
Patients with NSCLC may display a low ratio of p.T790M <i>vs.</i> activating EGFR mutations in plasma at disease progression: implications for personalised treatmentMarzia Del Re, Romano Danesi, Paola Bordi et al.|Oncotarget|2017Cited by 12